

Case report

A case report of Gitelman syndrome resulting from two novel mutations in SLC12A3 gene

Wojciech Wolyniec^{a,*}, Sonia Kaniuka- Jakubowska^b, Mato Nagel^c, Zuzanna Wolyniec^d,
 Lukasz Obolonczyk^b, Renata Swiatkowska-Stodulska^b, Krzysztof Sworczak^b,
 Marcin Renke^a

^a Department of Occupational and Internal Medicine, Institute of Maritime and Tropical Medicine, Medical University of Gdansk, Poland

^b Department of Endocrinology and Internal Medicine, Medical University of Gdansk, Poland

^c Center for Nephrology and Metabolic Disorders, Weisswasser, Germany

^d Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Poland

ARTICLE INFO

Article history:

Received 6 February 2015

Accepted 7 April 2015

Available online 10 July 2015

Keywords:

Hypokalaemia

Hypomagnesaemia

Diuretics

ABSTRACT

Introduction: Hypokalaemia is a common clinical problem. A potential but commonly overlooked cause of hypokalaemia is Gitelman syndrome.

Material and methods: A 26-year-old man was admitted to the hospital due to syncope with general and muscular weakness and muscle cramps. The patient's history revealed previous recurrent syncope events associated to hypokalaemia with the lowest serum potassium value being 2.6 mmol/l. At admission, blood pressure was normal and no changes were found at physical examination. Laboratory tests showed mild hypokalaemia (3.0 mmol/l), hypomagnesaemia (1.36 mg/dl), hypocalciuria (< 40 mg/24h), and metabolic alkalosis (HCO₃⁻ 29.7 mmol/l, BE 5.3 mmol/l).

Results: Further laboratory tests (FeK, TTKG) confirmed inappropriate kaliuresis. Conn's disease was excluded by hormonal and imaging assessments. Genetic testing was performed and two novel heterozygous mutations: c.35_36insA and c.1095+5G>A were found in transcript NM.000339.2 in SLC12A3 gene.

Conclusion: The patient was diagnosed with Gitelman syndrome and was treated with supplements of potassium and magnesium.

© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

* Corresponding author.

E-mail address: wolyniecwojtek@gmail.com (W. Wolyniec).

<http://dx.doi.org/10.1016/j.nefro.2015.04.006>

0211-6995/© 2015 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license. (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

El caso del síndrome de Gitelman causado por dos nuevas mutaciones en el gen SLC12A3

R E S U M E N

Palabras clave:

Hipopotasemia
Hipomagnesemia
Diuréticos

Introducción: La hipopotasemia es un problema clínico común. El síndrome de Gitelman es una posible causa de hipopotasemia a veces no reconocida.

Material y métodos: Un hombre de 26 años de edad ingresa en un hospital por causa de un síncope, debilidad generalizada y calambres musculares. La historia clínica del paciente reveló la incidencia del síncope con hipopotasemia recurrente con el valor más bajo de potasio en 2,6 mmol/l. En el ingreso, el paciente presentaba una presión arterial normal y la exploración física no reveló ninguna enfermedad. La evaluación del laboratorio demostró una hipopotasemia leve (K^+ 3,0 mmol/l), hipomagnesemia (Mg 1,36 mg/dl), hipocalciuria (<40 mg/24 h) y alcalosis metabólica (HCO_3^- 29,7 mmol/l, exceso de base 5,3 mmol/l).

Resultados: Otras pruebas de laboratorio (FeK, TTKG) confirman una caliusis inadecuada. La enfermedad de Conn fue excluida tras la evaluación hormonal y radiológica. Se realizaron las pruebas genéticas y 2 mutaciones heterocigóticas: c.35_36insA y c.1095+5G>A fueron encontradas en la transcripción NM.000339.2 del gen SLC12A3.

Conclusión: El paciente fue diagnosticado con el síndrome de Gitelman y fue tratado con suplementos de potasio y magnesio.

© 2015 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la CC BY-NC-ND licencia. (<http://creativecommons.org/licencias/by-nc-nd/4.0/>)

Introduction

Hypokalemia is a common clinical problem in endocrinologists' and nephrologists' practice. There are many obvious causes of hypokalemia such as diarrhea, vomiting or diuretics abuse. Other causes such as tubulopathies are rarely observed and their diagnosis is more challenging. There are many inherited and acquired tubulopathies causing hypokalemia, sometimes severe and life-threatening.¹

A relatively common but overlooked cause of hypokalemia is Gitelman syndrome (GS).² It is a recessive salt-losing tubulopathy caused by the SLC12A3 gene mutation. SLC12A3 gene encodes the thiazide-sensitive transporter NCCT (sodium chloride co-transporter). NCCT is located in the distal convoluted tubular cells (DCC), which are responsible for 7–10% of electrolyte tubular absorption.³

The most severe laboratory abnormalities found in GS are hypokalemia and hypomagnesaemia caused by renal K^+ and Mg^{2+} wasting. Other typical changes are metabolic alkalosis, hypocalciuria and hyperreninemic hyperaldosteronism.⁴ Mild to moderate hypophosphatemia is frequently observed.⁵ Severe hypophosphatemia with severe hyponatremia was also reported.^{6,7}

First symptoms of GS occur in children or young adults with normal growth and history of salt-craving behaviors (children eager to consume pickle or brine, salted cucumbers, oranges and lemons, children licking salt from potato crisps, etc.).⁸ Clinical presentation varies among patients. Some are asymptomatic but others develop life-threatening complications. Males manifest a more severe phenotype than females.⁸ The most common symptoms are muscular cramps and weakness, constipation, nocturia, polyuria, thirst, polydipsia, cardiac arrhythmias, paresthesias and increased salt appetite. Arterial

hypotension is common and in many cases the most prominent symptom, however, in aging GS population hypertension can occur.⁸ The correlation between biochemical abnormalities and symptoms is not strong.⁹ GS does not interfere with children's moods and social relationships.^{9,10} Otherwise symptoms are more common in adults and can have negative impact on their quality of life. Forty-five percent of GS patients consider their symptoms as a moderate to big problem.¹¹ Extreme exhaustion, muscular weakness, paresthesias, severe fatigue and hypotension are associated with mild to severe reduction in daily activities.⁹

Estimated prevalence of GS is 1:40,000⁸ and the prevalence of heterozygous is at least 1% in the European population. More than 180 different mutations in SLC12A3 have been described until now.¹²

Case report

A 26-year-old male was admitted to the hospital due to incidence of syncope, generalized and muscular weakness and muscle cramps. The patient's history revealed an episode of syncope with potassium level 3.16 mmol/l. In further follow up in outpatient assessment, recurrent incidence of hypokalemia (the lowest value 2.6 mmol/l) was observed. Blood pressure was normal 110/80, heart rate was 72 per minute; there was no changes in physical examination. Nor neurological findings, weight 74 kg, height 178 cm. On admission to hospital laboratory evaluation showed mild hypokalemia (K^+ 3.0 mmol/l), hypomagnesaemia (Mg^{2+} 1.36 mg/dl), hypocalciuria (<40 mg/24 h), and metabolic alkalosis (HCO_3^- 29.7 mmol/l, BE 5.3 mmol/l). Kidney function was good with eGFR > 60 ml/min. Imaging studies were unremarkable, so was the ECG.

Table 1 – The values diagnostic for hypokalemia.¹³⁻¹⁵

	Values diagnostic for inappropriate kaliuresis	Patient
Urinary K ⁺ [mmol/24 h]	>20 mmol/24 h If serum K ⁺ < 3.5 mmol/l	57 mmol/l (serum) K ⁺ = 3.0 mmol/l
FeK = [(urine K ⁺ × serum creatinine)/(serum K ⁺ × urine creatinine)] × 100%	>6.5% If serum K ⁺ < 3.5 mmol/l	12% (serum) K ⁺ = 3.0 mmol/l
TTKG = [urine K ⁺ × serum osmolality] / [serum K ⁺ × urine osmolality]	TTKG > 2 If serum K ⁺ < 3.5 mmol/l	7.3 (serum) K ⁺ = 3.0 mmol/l
uK/Cr – random urine K ⁺ to creatinine ratio	uK/Cr > 15 mmol/g If serum K ⁺ < 3.5 mmol/l	67 mmol/g (serum) K ⁺ = 3.0 mmol/l

Further investigations confirmed that hypokalemia was caused by renal potassium wasting. The 24-h potassium wasting, transtubular K⁺ gradient (TTKG), fractional K⁺ excretion (FeK) and random K/creatinine ratio (K/Cr) were typical for hyperkaliuria and are shown in Table 1.¹³⁻¹⁵ Daily magnesiumuria was 64 mg/24 h, with fractional magnesium (FeMg) excretion 15%.

Although blood pressure was normal, hormonal tests to exclude Conn's disease and the abdominal CT were performed, and did not reveal any abnormalities in adrenal glands. Secondary hyperaldosteronism with levels of aldosterone 289 pg/ml (normal range 20-180) and renin 205 mIU/ml (normal range 2.8-39.9) were typical for GS.

The patient was diagnosed as GS on the basis of a clinical phenotype. After the diagnosis, treatment with supplements of potassium and magnesium was introduced. He received 20 mmol of potassium chloride and 18 mmol of magnesium pyrrolidone carboxylate, with clinical improvement. Family history revealed mild asymptomatic hypokalemia in the patient's 35-year-old sister. But investigations showed neither hyperkaliuria nor hypomagnesaemia. GS was not diagnosed in this case.

Genetic analysis

According to the genetic analysis, algorithm proposed by Nozu¹⁶ SLC12A3 gene should be tested in patients with hypokalemic metabolic alkalosis, with full term birth, normal weight without nephrocalcinosis, with hypocalcemia and hypomagnesaemia.

In the described case genetic testing was performed and two heterozygous mutations: c.35.36insA and c.1095+5G>A were found in transcript NM.000339.2 of the SLC12A3 gene (Fig. 1). Both mutations are not yet in the HGMD(r) database version available [HGMD® Professional 2013.2 – 28th June 2013]. The first mutation was also found in patient's mother and the second in father. Only one of the two mutations identified in our patient c.35.36insA was found in his sister.

The mutations found in this patient almost prove the clinical diagnosis of GS. The pathogenetic relevance of the frameshift mutation is obvious. We cannot be sure about the pathogenetic relevance of the splice site mutation of intron 8. The consensus splice sequence G (100%), T (100%), A (62%), A (68%), G (82%), T (63%) at the splice donor of intron 8 does not exactly match the consensus GTgAGc. The mutation found in this patient further deviates the sequence from the consensus (GtgAac). Also, in silico analysis by mutation taster considers this mutation as disease causing.¹⁷

Discussion


Tubulopathies are rare diseases. According to RenalTube database¹⁸ the most common primary tubulopathies in European population are distal renal tubular acidosis, Bartter syndrome, familial hypomagnesaemia with hypercalciuria and GS.¹⁸ The prevalence of GS is around 25 cases per 1 million.³ Because GS is one of the most common, probably many nephrologists and endocrinologist will be confronted with cases of GS during their careers. Our patient had typical clinical presentation of GS and responded well to therapy. The problem with GS is that overlooked hypokalemia could cause death due to cardiac arrest or respiratory muscles paralysis. The severe neuromuscular symptom such as hypokalemic paralysis occurs in up to 6% of patients (more common in Asian patients).³

The inherited tubulopathies have a kind of "mirror images"-acquired tubulopathies caused by diuretics. Every diuretic (to be precise: natriuretics, acquaretics or glucuretics) cause abnormalities similar to those found in inherited tubulopathies (Table 2). Almost in every tubulopathy polyuria occurs, and potassium level changes are among the commonest problems. In patients with GS the mutations of SLC12A3 gene are found. This gene is encoding the thiazide-sensitive transporter. Therefore GS resembles chronic treatment with thiazides.


Approach to hypokalemia

GS is also known as familial hypokalemic hypomagnesaemia, because hypokalemia is the most common phenomenon. In a patient with hypokalemia and suspicion of tubulopathy one should confirm hyperkaliuria. Renal potassium wasting can be proved by calculating TTKG, FeK, random K/Cr ratio or after 24-h urine collection (Table 1). Assessment of kaliuria should be performed, when the patient is taking neither diuretics nor potassium supplementation and when the potassium level is low. When potassium excretion is below 30 mmol/l and TTKG is low, hypokalemia is caused by extrarenal loss or a transcellular K⁺ shift.

When excessive potassium renal loss in patient with hypokalemia is confirmed, further diagnosis is based on pH and blood pressure. In many cases these simple studies will be enough for diagnosis. An important problem of an increasing interest is primary aldosteronism (PA). Some clinical studies have suggested that PA is the cause of over 10% of arterial hypertension (AH), and is more common in patients with AH resistant to antihypertensive agents.¹⁹ Hypokalemia is one of



Nr	Transcript	Exon/Intro n	Codon n	Protein	DNA	PMID	Zygoty
1	NM_000339.2	1	12	p.D12EfsX17	c.35_36insA	n/a	heterozygous



Nr	Transcript	Exon/Intron	Codon	Protein	DNA	PMID	Zygoty
2	NM_000339.2	8	365	IVS8+5G>A	c.1095+5G>A	n/a	heterozygous

Fig. 1 – Chromatograms of affected patient's DNA sequencing.

the “classical” symptoms of PA, but is not so common as was considered.²⁰ Yet, because there is no gold standard in the diagnosis of AP, it is worth remembering about RAA axis in patients with AH and hypokalemia.¹⁹

Diagnosis of hypomagnesaemia

Hypomagnesaemia is a common abnormality in GS patients, although it is not observed in every case.²¹ In normomagnese-mic patients with GS, clinical manifestation and electrolyte abnormalities are milder.²²

Similar to potassium ions, magnesium ones are freely filtered by the glomeruli. 10% of filtered Mg^{2+} is absorbed by the proximal tubule, 50–70% in ascending limb of Henle's loop. Distal reabsorption depends on epithelial Mg^{2+} TRPM6 channels. Magnesiuria depends on oral intake and FeMg should be calculated to establish renal Mg^{2+} wasting ($FeMg = (\text{urine magnesium} \times \text{serum creatinine}) / [0.7(\text{serum magnesium} \times \text{urine creatinine})] \times 100$). FeMg less than 2% suggests poor intake, GI losses or shift of Mg into cells. FeMg above 4% suggests renal Mg^{2+} wasting. When renal Mg wasting is proved, random Ca/Cr ratio should be calculated. Urine Ca/Cr ratio <0.3 is typical in GS, isolated dominant

Table 2 – Diuretics and tubulopathies.

Inherited single gene defect	Potassium concentration	Symptoms similar to use of:	Gene	Gene product	Gene product location
Guibaud-Vainsel syndrome (RTA 3)	↓	Acetazolamide	CA2	CA II	Proximal tubule
Renal glycosuria	–	SGLT2 inhibitors ^a (Canagliflozin, Tofogliflozin, Dapagliflozin)	SLC5A2	Sodium/glucose cotransporter 2 (SGLT2)	Proximal tubule
Bartter syndrome	↓	Furosemide	SLC12A1 ^b	Na-K-2Cl cotransporter (NKCC2)	Loop of Henle
Gitelman syndrome	↓	Thiazide	SLC12A3	Thiazide-sensitive Na-Cl cotransporter	Distal tubule
Diabetes insipidus	–	Vaptan	AVPR2, AQP2	V2 receptor	Collecting duct
Pseudohypoaldosteronism, AD	←↑	Spiroglactone	NR3C2	Spiroglactone-sensitive mineralocorticoid receptor	Collecting duct
Pseudohypoaldosteronism, AR	↑	Amiloride	SCNN1A, SCNN1B, SCNN1G	Amiloride-sensitive epithelial sodium channel	Collecting duct

AR – autosomal recessive; AD – autosomal dominant.

^a SGLT2 inhibitors (glucuretics) are the new drugs for the management of type 2 diabetes; during treatment osmotic diuresis-related events such as pollakiuria and polyuria are observed.

^b Although there are different Bartter genes this is the one that mimics furosemid.

hypomagnesaemia with hypocalciuria and in thiazide treatment. Urine Ca/Cr ratio >0.3 is typical in hypermagesuria in Bartter syndrome, so are isolated recessive hypomagnesaemia with normocalciuria, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, autosomal dominant hypocalcemia with hypercalciuria, loop diuretics treatment and nephropathy caused by some nephrotoxins.²³

Magnesium and potassium homeostasis are related to each other, and potassium depletion cannot be corrected until the correction of hypomagnesaemia.²³ On average patients should receive up to 500 mEq of potassium, 4–5 mg/kg/day of 5–10 mg of magnesium chloride. Amiloride (5–10 mg/day) and spiroglactone (200–300 mg) are helpful.³

Clinical symptoms and laboratory results are essential for diagnosis. In cases with typical phenotype some authors recommend performing a thiazide test to confirm diagnosis.²⁴ In presented case genetic investigation revealed two novel mutations of SLC12A3 gene. They are probably caused by lack of functional mutations of NCCT.

Conclusions

GS syndrome is one of the rare causes of hypokalemia, and it seems a challenge for physicians. We show in this paper

that if one remembers about a very simple approach to hypokalemia and is aware of diuretics action and their similarity to inherited tubulopathies, the diagnosis could be quite straightforward. GS should be differentiated from other tubulopathies (inherited as well as acquired), and other causes of hypokalemia (e.g. Conn's disease). Familial history can reveal asymptomatic patients with GS. Suitable treatment protects patients from potentially dangerous complications.

REFERENCES

1. Wolyniec W. Diagnosis of severe hypokalemia in 40 years old patient with Sjogren syndrome. *Forum Nefrologiczne*. 2008;1:91–5.
2. Hoskote SS, Joshi SR, Ghosh AK. Disorders of potassium homeostasis: pathophysiology and management. *J Assoc Physicians India*. 2008;56:685–93.
3. Graziani G, Fedeli C, Moroni L, Cosmai L, Badalamenti S, Ponticelli C. Gitelman syndrome: pathophysiological and clinical aspects. *QJM*. 2010;103:741–8.
4. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat Genet*. 1996;12:24–30.

5. Vigano C, Amoroso C, Barretta F, Minnici G, Albisetti W, Syrén ML, et al. Renal phosphate handling in Gitelman syndrome – the results of a case-control study. *Pediatr Nephrol.* 2013;28:65–70.
6. Ali A, Masood Q, Yaquub S, Kashif W. A case of Gitelman syndrome with severe hyponatraemia and hypophosphataemia. *Singapore Med J.* 2013;54:e18–20.
7. Marques M, Silva C, Ferreira E, Maia P, Carreira A, Campos M. Gitelman syndrome with hyponatremia, a rare presentation. *Nefrologia.* 2014;34:266–8.
8. Knoers NV, Levchenko EN. Gitelman syndrome. *Orphanet J Rare Dis.* 2008;3:22.
9. Caiata-Zufferey M, Zanini CA, Schulz PJ, Syren ML, Bianchetti MG, Bettinelli A. Living with Gitelman disease: an insight into patients' daily experiences. *Nephrol Dial Transplant.* 2012;27:3196–201.
10. Herrero-Morín JD, Rodríguez J, Coto E, et al. Gitelman syndrome in Gypsy paediatric patients carrying the same intron 9+1 G>T mutation. Clinical features and impact on quality of life. *Nephrol Dial Transplant.* 2011;26:151–5.
11. Cruz DN, Shaer AJ, Bia MJ, Lifton RP, Simon DB. Gitelman's syndrome revisited: an evaluation of symptoms and health-related quality of life. *Kidney Int.* 2001;59:710–7.
12. Ren H, Qin L, Wang W, Ma J, Zhang W, Shen PY, et al. Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. *Am J Nephrol.* 2013;37:152–7.
13. Assadi F. Diagnosis of hypokalemia: a problem-solving approach to clinical cases. *Iran J Kidney Dis.* 2008;2:115–22.
14. Elisaf M, Siamopoulos KC. Fractional excretion of potassium in normal subjects and in patients with hypokalaemia. *Postgrad Med J.* 1995;71:211–2.
15. Choi MJ, Ziyadeh FN. The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. *J Am Soc Nephrol.* 2008;19:424–6.
16. Ishimori S, Kaito H, Matsunoshita N, Otsubo H, Hashimoto F, Ninchoji T, et al. SLC26A3 gene analysis in patients with Bartter and Gitelman syndromes and the clinical characteristics of patients with unidentified mutations. *Kobe J Med Sci.* 2013;59:E36–43.
17. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods.* 2010;7:575–6.
18. Mejia N, Santos F, Claverie-Martin F, Garcia-Nieto V, Ariceta G, Castano L. RenalTube: a network tool for clinical and genetic diagnosis of primary tubulopathies. *Eur J Pediatr.* 2013;172:775–80.
19. Myśliwiec J, Zukowski L, Grodzka A, Piłaszewicz A, Dąrowski S, Górska M. Problems in diagnostics of primary aldosteronism – analysis of the own data. *Endokrynol Pol.* 2010;61:2–5.
20. Molina A, Mon C, Olié A, Ortiz M. Clinical variability of Gitelman's syndrome. *Nefrologia.* 2006;26:504–6.
21. Jiang L, Chen C, Yuan T, Qin Y, Hu M, Li X, et al. Clinical severity of Gitelman syndrome determined by serum magnesium. *Am J Nephrol.* 2014;39:357–66.
22. Hyla-Klekot L, Kokot F. Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients. *Pol Arch Med Wewn.* 2013;123:547–51.
23. Assadi F. Hypomagnesemia: an evidence-based approach to clinical cases. *Iran J Kidney Dis.* 2010;4:13–9.
24. Colussi G, Bettinelli A, Tedeschi S, De Ferrari ME, Syrén ML, Borsa N, et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. *Clin J Am Soc Nephrol.* 2007;2:454–60.